Document:

EX-4.7

 Exhibit 4.7 

WARRANT ASSIGNMENT AND ASSUMPTION AGREEMENT 

This Warrant Assignment and Assumption Agreement (this “Agreement”) is entered into as of [•], 2023, by and among
European Biotech Acquisition Corp., a Cayman Islands exempted company (the “Company”), Oculis Holding AG, a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland (“New
Parent”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”). 

WHEREAS, the Company and the Warrant Agent are parties to that certain Warrant Agreement, dated as of March 15, 2021 (the
“Existing Warrant Agreement”); 
 WHEREAS, capitalized terms used herein, but not otherwise defined, shall have the
meanings given to such terms in the Existing Warrant Agreement; 
 WHEREAS, pursuant to the Existing Warrant Agreement (together with
the partial exercise of the Over-allotment Option), the Company issued (i) 151,699 warrants to the Sponsor (collectively, the “Private Placement Warrants”) to purchase the Company’s Class A ordinary shares, par value
$0.0001 per share (“Class A Shares”), with each Private Placement Warrant being exercisable for one Class A Share and with an exercise price of $11.50 per share, and (ii) 4,251,595 warrants as part of units
to public investors in the Offering (the “Public Warrants” and together with the Private Placement Warrants, the “Warrants”) to purchase Class A Shares, with each whole Public Warrant being exercisable for one
Class A Share and with an exercise price of $11.50 per share; 
 WHEREAS, all of the Warrants are governed by the Existing
Warrant Agreement; 
 WHEREAS, on October 17, 2022, the Company and Oculis SA, a public limited liability company
(société anonyme) incorporated and existing under the laws of Switzerland, entered into that certain Business Combination Agreement (as may be amended, modified or supplemented from time to time, the “BCA”);

 WHEREAS, the BCA provides, among other things, that Oculis Merger Sub I Company, a Cayman Islands exempted company that is a
direct, wholly-owned subsidiary of New Parent will merge with and into the Company (the “First Merger”), with the Company surviving the First Merger as a direct, wholly-owned subsidiary of New Parent; 

WHEREAS, in connection with the First Merger, the BCA provides, among other things, that: (i) the Class A Shares shall be
automatically converted into one class of common stock of the Company, as the surviving company of the First Merger (the “Surviving EBAC Shares”), (ii) the Warrants outstanding immediately prior to the time at which the First Merger
becomes effective (the “First Merger Effective Time”) will be automatically converted into warrants of the Company, as the surviving company of the First Merger (“Surviving EBAC Warrants”) and (iii) the Company
shall deposit, or cause to be deposited, with an exchange agent (held solely on behalf of the holders of Class A Shares and Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms and subject to the conditions set forth in
the BCA and the Ancillary Agreements (as defined in the BCA); 

 WHEREAS, on the day before the Acquisition Closing Date (as defined in the BCA) and
following the First Merger Effective Time but prior to the Second Merger Effective Time (as defined below), an exchange agent will, among other things, contribute the Surviving EBAC Shares and assign the Surviving EBAC Warrants to New Parent (the
“Exchange Agent Contribution”) in exchange for (i) New Parent ordinary shares, nominal value CHF 0.01 (“New Parent Shares”) and (ii) a right to acquire New Parent Shares (“New Parent
Warrants”), in each case of (i) and (ii), to be held by the exchange agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the “New Parent Interests Consideration”); 

WHEREAS, in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date (as defined in the BCA) and
prior to the Second Merger Effective Time, the exchange agent will undertake to distribute the (i) New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (ii) New Parent Warrants as
part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants (“Exchange Agent Contribution Actions”); 

WHEREAS, upon consummation of the Exchange Agent Contribution Actions, and as provided in Section 4.5 of the Existing Warrant
Agreement, the Warrants will no longer be exercisable for Class A Shares but instead will be exercisable (subject to the terms and conditions of the Existing Warrant Agreement as amended hereby) for New Parent Shares; 

WHEREAS, on the day before the Acquisition Closing Date (as defined in the BCA) and following the completion of the Exchange Agent
Contribution Actions, at the Second Merger Effective Time, among other things, the Company will merge with and into Oculis Merger Sub II Company, a Cayman Islands exempted company that is a direct, wholly-owned subsidiary of New Parent
(“Merger Sub 2”), the separate corporate existence of the Company will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent (the “Second Merger” and the time at
which the Second Merger becomes effective, the “Second Merger Effective Time”; 
 WHEREAS, the Board of Directors of
the Company has determined that the consummation of the transactions contemplated by the BCA (the “Transactions”) will constitute a Business Combination (as defined in the Recitals of the Existing Warrant Agreement); 

WHEREAS, in connection with the Exchange Agent Contribution Actions and the other Transactions, the Company desires to assign all of
its right, title and interest in the Existing Warrant Agreement to New Parent and New Parent wishes to accept such assignment; and 

  
 2 

 WHEREAS, Section 9.8 of the Existing Warrant Agreement provides that the Company
and the Warrant Agent may amend the Existing Warrant Agreement without the consent of any Registered Holder for the purpose of curing any ambiguity or correcting any mistake, or curing, correcting or supplementing any defective provision contained
therein or adding or changing any other provisions with respect to matters or questions arising under the Existing Warrant Agreement as the Company and the Warrant Agent may deem necessary or desirable and that the Company and the Warrant Agent deem
shall not adversely affect the rights of the Registered Holders thereunder. 
 NOW, THEREFORE, in consideration of the mutual
agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows. 

1. Assignment and Assumption; Consent. 

1.1. Assignment and Assumption. The Company hereby assigns to New Parent all of the Company’s right, title and interest in and to
the Existing Warrant Agreement (as amended hereby) upon the completion of the Exchange Agent Contribution Actions (the “Effective Time”) and New Parent hereby assumes, and agrees to pay, perform, satisfy and discharge in full, as
the same become due, all of the Company’s liabilities and obligations under the Existing Warrant Agreement (as amended hereby) arising from and after the Effective Time. 

1.2. Consent. The Warrant Agent hereby consents to the assignment of the Existing Warrant Agreement by the Company to New Parent
pursuant to Section 1.1 hereof effective as of the Effective Time, and the assumption of the Existing Warrant Agreement by New Parent from the Company pursuant to Section 1.1 hereof effective as of
the Effective Time, and to the continuation of the Existing Warrant Agreement in full force and effect from and after the Effective Time, subject at all times to the Existing Warrant Agreement (as amended hereby) and to all of the provisions,
covenants, agreements, terms and conditions of the Existing Warrant Agreement and this Agreement. 
 2. Amendment of Existing
Warrant Agreement. The Company and the Warrant Agent hereby amend the Existing Warrant Agreement (including all Exhibits thereto) as provided in this Section 2, effective as of the Effective Time, and acknowledge and
agree that the amendments to the Existing Warrant Agreement set forth in this Section 2 are to provide for the delivery of Alternative Issuance pursuant to Section 4.5 of the Existing Warrant Agreement (in connection
with the Transactions) and are necessary or desirable and that such amendments do not adversely affect the rights of the Registered Holders thereunder. 

2.1. Preamble. The preamble on page one of the Existing Warrant Agreement is hereby amended by deleting “European Biotech
Acquisition Corp., a Cayman Islands exempted company” and replacing it with “Oculis Holding AG, a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland”. As a result thereof, all
references to the “Company” in the Existing Warrant Agreement (including Exhibits thereto) shall be references to Oculis Holding AG rather than European Biotech Acquisition Corp. 

  
 3 

 2.2. Reference to New Parent Shares. All references to “Ordinary Shares” in
the Existing Warrant Agreement (including all Exhibits thereto) shall mean “Oculis Holding AG Ordinary Shares” or “ordinary shares in the share capital of Oculis Holding AG.” 

2.3. Detachability of the Warrants. Section 2.4 of the Existing Warrant Agreement is hereby deleted and replaced with the
following: “[INTENTIONALLY OMITTED”]. 
 2.4. References to Business Combination. All references to “Business
Combination” in the Existing Warrant Agreement (including all Exhibits thereto) shall be references to the Transactions, and references to “the completion of the Business Combination” and all variations thereof in the Existing Warrant
Agreement (including all Exhibits thereto) shall be references to the consummation of the Acquisition Closing (as defined in the BCA). 

2.5. Issuance of Ordinary Shares on Exercise. Section 3.3.2. is hereby amended by adding the following sentence: “The acquisition
of Oculis Holding AG Ordinary Shares through the exercise of warrants and the further transfer of Oculis Holding AG Ordinary Shares shall be subject to the restrictions specified in Article 4 of the Articles of Association.” 

2.6. Replacement of Securities upon Reorganization, etc. The last two sentences of Section 4.5 of the Existing Warrant Agreement
are hereby amended by deleting the words “this Section 4.4” and replacing it with the words “this Section 4.5.” 

2.7. Transfer of Warrants: Section 5.6 is hereby amended by adding the following sentence: “Any transfer of Warrants shall be
subject to the restrictions specified in Article 4 of the Articles of Association of Oculis Holding AG.” 
 2.8. Reservation of
Ordinary Shares. Section 7.3. is hereby amended and restated in its entirety as follows: “The Company shall at all times reserve and keep available a number of conditional capital in its Articles of Association that shall be sufficient to
permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.” 
 2.9. Notice. The address for
notices to the Company set forth in Section 9.2 of the Existing Warrant Agreement is hereby amended and restated in its entirety as follows: 

Oculis Holding AG 
 Bahnhofstrasse
7 
 CH-6300 

Zug, Switzerland 
 Attention: Riad
Sherif, Chief Executive Officer 
 Email: riad.sherif@oculis.com 

with a copy to: 
 Cooley (UK) LLP 

22 Bishopsgate 
 London EC2N 4BQ,
UK 
 Attention: Michal Berkner 

Divakar Gupta 
 Ryan Sansom 

E-mail: mberkner@cooley.com 

dgupta@cooley.com 

rsansom@cooley.com 

  
 4 

 3. Miscellaneous Provisions. 

3.1. Effectiveness of this Agreement. Each of the parties hereto acknowledges and agrees that the effectiveness of this Agreement shall
be expressly subject to the concurrent occurrence of the Exchange Agent Contribution Actions and shall automatically be terminated and shall be null and void if the BCA shall be terminated for any reason. 

3.2. Successors. All the covenants and provisions of this Agreement by or for the benefit of New Parent or the Warrant Agent shall bind
and inure to the benefit of their respective successors and assigns. 
 3.3. Severability. This Agreement shall be deemed severable,
and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or
provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable. 

3.4. Applicable Law. The validity, interpretation and performance of this Agreement shall be governed in all respects by the laws of
the State of New York, without giving effect to conflict of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereby agree that any action, proceeding or claim against a party arising
out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which
jurisdiction shall be exclusive. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 

3.5. Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the
Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it. 

3.6. Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

3.7. Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect
the interpretation thereof. 

  
 5 

 3.8. Entire Agreement. This Agreement and the Existing Warrant Agreement, as modified
by this Agreement, constitutes the entire understanding of the parties and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to the subject matter hereof,
and all such prior agreements, understandings, arrangements, promises and commitments are hereby canceled and terminated. 
 [Remainder of
page intentionally left blank.] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first above written. 
  

			
	EUROPEAN BIOTECH ACQUISITION CORP.
		
	By:	 	 
		 	Name:     
		 	Title:     

 
			
	OCULIS HOLDING AG
		
	By:	 	 
		 	Name: Riad Sherif
		 	Title: Chief Executive Officer

 
			
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent
		
	By:	 	 
		 	Name:
		 	Title:EX-10.10

 Exhibit 10.10 

INDEMNIFICATION AGREEMENT 

dated [DATE] 
 by and among 

Oculis Holding AG 
 Bahnhofstrasse 7 

6300 Zug 
 Switzerland 

(“Oculis”) 
 And 

[Name of Director / Executive] 
 [address] 

(the “Indemnitee “) 

(the Indemnitee and together with the Company, 

the “Parties” and each a “Party”) 

regarding the indemnification of the Indemnitee by the Company 

  

			
	Indemnification Agreement Oculis Holding AG	  	2/11

 Table of Contents 
  

							
			
	 Preamble
	 	3	  			
			
	 1.
	 	Definitions	  	 	3	 
			
	 2.
	 	Indemnification	  	 	4	 
			
	 3.
	 	Successful Defense and Partial Indemnification	  	 	5	 
			
	 4.
	 	Indemnification Procedure	  	 	6	 
			
	 4.1
	 	Notification and Indemnification Request	  	 	6	 
			
	 4.2
	 	Advance of Expenses	  	 	6	 
			
	 4.3
	 	Payment to Cover Losses	  	 	6	 
			
	 5.
	 	Non-Exclusivity; Insurance; Subrogation	  	 	6	 
			
	 6.
	 	Remedies of the Indemnitee	  	 	7	 
			
	 7.
	 	Company’s Right to Participate	  	 	7	 
			
	 8.
	 	Term of the Agreement	  	 	8	 
			
	 9.
	 	Data Protection	  	 	8	 
			
	 10.
	 	General Provisions	  	 	8	 
			
	 10.1
	 	No Right to Continued Service	  	 	8	 
			
	 10.2
	 	Successors and Assignment	  	 	9	 
			
	 10.3
	 	Notices	  	 	9	 
			
	 10.4
	 	Entire Agreement	  	 	9	 
			
	 10.5
	 	Severability	  	 	9	 
			
	 10.6
	 	Amendments	  	 	9	 
			
	 10.7
	 	Waiver of Rights	  	 	9	 
			
	 10.8
	 	Counterparts	  	 	9	 
			
	 11.
	 	Governing Law and Jurisdiction	  	 	10	 
			
	 11.1
	 	Governing Law	  	 	10	 
			
	 11.2
	 	Jurisdiction	  	 	10	 

 Preamble 

A 
 The Company is a Swiss corporation registered with the
commercial register of the Canton of Zug under the company identification number CHE-396.695.611. 
 B 

The Indemnitee has been elected by the general meeting of shareholders of the Company as a member of the board of directors of the Company (the Board) and /
or appointed by the Board as an executive officer of the Company (Executive Officer), as the case may be. The Indemnitee in his or her capacity as a member of the Board and/or an Executive Officer may be exposed to litigation and other risks arising
out of or in connection with his or her service on the Board and / or as an Executive Officer. 
 C 

The Company desires to attract and retain highly qualified individuals to serve on the Board and as Executive Officers. Therefore, the Company intends to
indemnify the members of the Board and Executive Officers in order to provide them with as much protection as permitted by applicable laws and regulations. 

D 
 The articles of association of the Company (the
“Articles”) that will become effective upon the closing of the business combination, by and between European Biotech Acquisition Corp., a Cayman Islands exempted company (including any successor entity thereto), and Oculis SA, a
“Aktiengesellschaft” / “société anonyme” incorporated and existing under the laws of Switzerland (the Business Combination), provide that the Company shall indemnify and hold harmless, to the extent permitted
by law, the members of the Board and the Executive Officers as set forth therein. 
 E 

This Indemnification Agreement (the “Agreement”) shall be a supplement to and in furtherance of the indemnification provided in the Articles,
any resolution of the Board in this regard and any D&O Insurance. This Agreement shall not be deemed a substitute nor diminish or abrogate any rights of the Indemnitee under the Articles, any resolution of the Board in this regard and any
D&O Insurance. 
 Now, therefore, the Parties agree as follows: 
  

	1.	 DEFINITIONS 

Capitalized terms used in this Agreement shall have the meanings assigned to them in the body of this Agreement or hereinafter, as applicable: 

 

			
	Business Day	  	means any day, other than a Saturday or a Sunday, on which the commercial banks at the domicile of the Company are open for business throughout the day.
		
	CO	  	means the Swiss Code of Obligations (Loi fédérale complétant le Code civil suisse (Livre cinquième: Droit des obligations) / Bundesgesetz betreffend die Ergänzung des Schweizerischen
Zivilgesetzbuches (Fünfter Teil: Obligationenrecht)) of 30 March 1911, as amended from time to time.

  

			
	Indemnification Agreement Oculis Holding AG	  	4/11

			
	Expense	  	means any and all attorneys’ fees, retainers, court and administrative costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs and printing and binding costs, telephone charges, postage,
delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with investigating, defending, prosecuting, participating, settling, appealing, or being a witness in, a Proceeding (or preparing for any
of the foregoing), in each case actually and reasonably incurred by the Indemnitee.
		
	Loss(es)	  	means all losses, damages, liabilities, judgments, fines, penalties, amounts due or paid in settlement (if such settlement has been approved by the Company whereby such approval shall not be unreasonably withheld) and Expenses, in
each case actually and reasonably incurred by the Indemnitee.
		
	Proceeding	  	means any threatened, pending or completed action, suit, claim, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other proceeding, whether brought by or in the right of the
Company or otherwise, whether civil, criminal, administrative or investigative, including appeals and petitions therefrom, except for one initiated by the Indemnitee to enforce his or her rights under this Agreement.

  

	2.	 INDEMNIFICATION 

a) Subject to the limitations set forth in this Agreement, the Company shall indemnify and hold harmless the Indemnitee if he or she was, is or
is threatened to be made party to, or participant in, or otherwise is involved (including as a witness) in, any Proceeding, by reason of: 

(i) any actual or alleged acts, consents or omissions in connection with the execution of his or her duties, or alleged duties, as a member of
the Board and/or as an Executive Officer; 
 (ii) the fact that he or she is or was a member of the Board and/or an Executive Officer; 

(iii) the fact that while serving as a member of the Board and/or as an Executive Officer he or she is or was serving as a director, executive
officer, employee or agent of any of the Company’s subsidiaries; 
 (iv) the fact that while serving as a member of the Board and/or as
an Executive Officer he or she is or was serving at the request of the Company as a director, executive officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise; 

from and against all Losses in connection with such Proceeding, in each case: 

 

	 	(1)	 to the fullest extent permitted by the Swiss Code of Obligations (the “CO”), other applicable
laws and regulations and the Articles, as may be amended from time to time; and 

  

	 	(2)	 provided that the Indemnitee acted in good faith and in a manner which he or she reasonably believed to be in
the best interest of the Company, and in addition, with respect to any criminal Proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The termination of any Proceeding by judgment, order, (in or out of court)
settlement or conviction, or upon a plea of no contest (nolo contendere) or its equivalent, shall not, of itself, create a presumption that the Indemnitee did not satisfy the foregoing applicable standard of conduct. 

  

			
	Indemnification Agreement Oculis Holding AG	  	5/11

 b) Notwithstanding any provision in this Agreement to the contrary, the Company shall not be
obliged to indemnify the Indemnitee in connection with any Proceeding, and the Indemnitee shall repay any Expenses advanced by the Company: 

(i) in respect of any claim, issue or matter as to which the Indemnitee shall have (A) been adjudged in a final and non-appealable judgment or decree of a court, arbitral tribunal or governmental or administrative authority of competent jurisdiction to have committed an intentional or grossly negligent breach of his or her duties
as a member of the Board and / or the Executive Committee under applicable laws and regulations, the Articles and the Company’s internal regulations and policies, and / or the Indemnitee’s mandate, service, employment or other agreement,
or (B) acknowledged an intentional or grossly negligent breach of his or her duties as a member of the Board and / or as an Executive Officer under applicable laws and regulations, the Articles, the Company’s internal regulations or
policies and / or the Indemnitee’s mandate, service, employment or other agreement in a written in or out of court or tribunal acknowledgment or settlement; or 

(ii) if such indemnification were prohibited by the CO or other applicable laws and regulations. 

c) To the fullest extent permitted under the CO and other applicable laws and regulations, the Company waives, and will cause any of its
subsidiaries to waive, any claims it may have against the Indemnitee for any loss, damage, costs or expenses incurred or sustained by the Company and / or any of its subsidiaries by reason of any acts, consents or omissions by the Indemnitee in
connection with the execution of his or her duties as a member of the Board and / or as an Executive Officer, unless any such loss, damage, costs or expenses is or are attributable to conduct (including omissions) constituting an intentional or
grossly negligent breach of his or her duties as a member of the Board and / or as an Executive Officer under applicable laws and regulations, the Articles, the Company’s internal regulations or policies and / or the Indemnitee’s mandate,
service, employment or other agreement. 
 d) To the extent that the Indemnitee is, by reason of his or her capacity as a member of the Board
and / or as an Executive Officer, a witness or required attendee in any Proceeding, he or she shall be indemnified by the Company against all Expenses in connection therewith. 

e) Any indemnification under this Agreement (unless ordered by a court or arbitral tribunal), other than the advance of Expenses pursuant to
Section 4.2, will be made by the Company only upon a determination relating to a specific case that indemnification of the Indemnitee is proper in the circumstances because he or she has satisfied the applicable standard of conduct set forth in
Section 2a) and is not subject to the limitations set forth in Section (b). 
  

	3.	 SUCCESSFUL DEFENSE AND PARTIAL INDEMNIFICATION 

a) To the extent that the Indemnitee has been successful on the merits or otherwise, including the dismissal of an action without prejudice, in
defense of any Proceeding pursuant to Section 2a), or in defense of any claim, issue or matter therein, the Company shall, subject to the limitations set forth in this Agreement, indemnify the Indemnitee against all Expenses in connection
therewith. 
 b) If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion
of any Expenses in connection with the investigation, defense, settlement or appeal of a Proceeding, but not for the total amount thereof, the Company shall nevertheless indemnify the Indemnitee for the portion thereof to which Indemnitee is
entitled. 

  

			
	Indemnification Agreement Oculis Holding AG	  	6/11

	4.	 INDEMNIFICATION PROCEDURE 

 

	4.1	 Notification and Indemnification Request 

a) The Indemnitee shall promptly notify the Company in writing upon being served with any claim, summons, citation, subpoena, complaint,
indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification of Losses and / or advancement of Expenses covered hereunder (any such proceeding (whether notified by the Indemnitee or otherwise
known to the Company), a Relevant Proceeding). The failure of the Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement, unless and only to the extent that such
failure actually and materially prejudices the Company. 
 b) In order to obtain indemnification of Losses and / or an advance of Expenses
under this Agreement, the Indemnitee shall submit to the Company a written request, including such documentation and information as is reasonably available to the Indemnitee and is reasonably necessary to determine whether and to what extent the
Indemnitee is entitled to such indemnification or advance, including the person(s) making (or threatening to make) the respective Proceeding, the circumstances leading to such a Proceeding, the cause of action for the Proceeding and the possible
costs associated with the Proceeding. 
  

	4.2	 Advance of Expenses 

a) Without prejudice to the entitlement of the Indemnitee to indemnification of Losses under this Agreement, the Company shall advance to the
Indemnitee all Expenses in connection with (i) any Proceeding pursuant to Section 2a), (ii) any proceeding or action reasonably brought by the Indemnitee to seek recovery under the D&O Insurance (as defined below) and (iii) any
proceeding or action reasonably brought by the Indemnitee to enforce this Agreement pursuant to Section 6, in each case within 20 (twenty) Business Days after receipt by the Company of a statement pursuant to Section 4.1 from the
Indemnitee requesting such advance from time to time and evidencing such Expenses, whether prior to or after the final disposition of such proceeding. 

b) The Indemnitee shall repay any Expenses advanced by the Company if it shall ultimately be determined that the Indemnitee is not entitled to
be indemnified against such Expenses. 
  

	4.3	 Payment to Cover Losses 

Notwithstanding any right for repayment the Company may have under this Agreement and subject to the determination by the Company pursuant to
Section e), any payment to the Indemnitee to cover Losses pursuant to the indemnification entitlement according to Section 2 shall be made no later than 20 (twenty) Business Days after the Company has received the written request of the
Indemnitee pursuant to Section 4.1. 
  

	5.	 NON-EXCLUSIVITY; INSURANCE; SUBROGATION 

a) The rights of indemnification of Losses and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive
of, and shall not limit, any other rights to which the Indemnitee may at any time be entitled under applicable law, the Articles, a resolution of the general meeting of shareholders of the Company or the Board, the D&O Insurance (as defined
below), any other agreement or otherwise. 
 b) To the extent that the Company maintains an insurance policy or policies providing liability
insurance for members of the Board and / or Executive Officers (the “D&O Insurance”), the Indemnitee shall be covered by such D&O Insurance in accordance with its terms to the maximum extent of the coverage available for any
such members of the Board and/or the Executive Committee under such D&O Insurance. 

  

			
	Indemnification Agreement Oculis Holding AG	  	7/11

 c) Any claim of the Indemnitee for advance or indemnification payment shall be limited by any
coverage by the Company’s D&O Insurance. To the extent that the terms of a D&O Insurance exclude coverage in case that the Company has an obligation to advance Expenses or indemnify the Indemnitee, the Company’s obligations
hereunder shall be deemed limited such that the D&O Insurance coverage applies. 
 d) Notwithstanding anything set out in this Agreement
to the contrary, the Indemnitee and the Company shall take all actions as may be required to comply with the terms of any policy of a D&O Insurance. 

e) If, at the time the Company receives notice of a Relevant Proceeding by the Indemnitee, the Company maintains a D&O Insurance and
without limitation to the Company’s obligations under this Agreement, the Company shall give prompt notice of such Proceeding to the insurance company providing the D&O Insurance and take all necessary or desirable actions to cause such
insurance company to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms and conditions of the D&O Insurance, provided that this obligation shall not relieve the Indemnitee from any
of his or her obligations under the D&O Insurance. 
 f) The Company shall indemnify the Indemnitee against all Expenses in connection
with any proceeding or action reasonably brought by the Indemnitee to seek recovery under the D&O Insurance. 
 g) The Company shall not
be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that the Indemnitee is entitled to receive such payment under the D&O Insurance or has otherwise received such payment under any
insurance policy, contract, agreement or otherwise. 
 h) In the event of any payment under this Agreement, the Company shall be subrogated
to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including the execution of such documents necessary to enable the Company
effectively to bring suit to enforce such rights. 
  

	6.	 REMEDIES OF THE INDEMNITEE 

If the Indemnitee initiates any action, suit, claim or any other proceeding to enforce his or her rights under this Agreement, the Indemnitee
shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all Expenses in connection with such proceeding; provided, however, that if the competent court determines that any of the material assertions
made by the Indemnitee in such proceeding was not made in good faith or was frivolous or if the final and non-appealable judgment or decree of a court confirms the Company’s decision that the Indemnitee
is not entitled to recover from the Company, then the Expenses in connection with such proceeding shall be borne by the Indemnitee, and the Indemnitee shall repay to the Company any advance payments. If it shall be determined in such proceeding that
the Indemnitee is entitled to receive part but not all of the indemnification or advance of Expenses sought, the Expenses in connection with such proceeding shall be appropriately prorated and the Indemnitee shall repay to the Company the respective
portion of the advance payments. 
  

	7.	 COMPANY’S RIGHT TO PARTICIPATE 

a) The Indemnitee shall allow the Company upon its request, and following consultation with the Indemnitee, to conduct such actions as the
Company may deem appropriate in connection with any such Proceeding. In this connection, the Indemnitee shall give to the Company all assistance it may reasonably require in the conduct of such actions ad also allow to assume the defense except in
cases where taking such action is in the Indemnitee’s reasonable opinion adverse to his legitimate interests. 

  

			
	Indemnification Agreement Oculis Holding AG	  	8/11

 b) After notice from the Company to the Indemnitee of its election to assume the defense of a
Relevant Proceeding, the Company shall not be liable to the Indemnitee under this Agreement for any Expenses subsequently incurred by the Indemnitee in connection with the defense of such Relevant Proceeding other than reasonable costs of
investigation or as otherwise provided below. The Indemnitee shall have the right to employ his or her own counsel in such Relevant Proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the
defense thereof shall be at the sole expense of the Indemnitee unless (i) the Indemnitee’s counsel shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the
defense of such Relevant Proceeding or (ii) ) the Indemnitee’s counsel shall have reasonably concluded that the Company’s actions or non-action are adverse to his legitimate interests or
(iii) the Company shall not in fact have employed counsel to assume the defense of such Relevant Proceeding, in each of which cases the reasonable fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company.
Furthermore, in any of the cases (i) to (iii) of the preceding sentence, the Indemnitee Person shall be entitled to (re)assume the control of the defense in the proceeding concerning such Indemnitee. 

c) The Company shall not be liable to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding
effected without its written consent. The Indemnitee shall not make any admission without the Company’s written consent unless the Indemnitee shall have determined to undertake his or her own defense in such matter and has waived his rights and
benefits under this Agreement. The Company shall not settle any Proceeding in any manner that would impose any penalty or limitation on or disclosure obligation with respect to the Indemnitee without the Indemnitee’s written consent. Neither
the Company nor the Indemnitee will unreasonably withhold the consent to any proposed settlement. 
 d) Irrespective of which Party to this
Agreement participates in a Proceeding, both the Company and the Indemnitee undertake to cooperate and to provide each other with all information reasonably necessary in order to defend any claims against the Indemnitee. 

 

	8.	 TERM OF THE AGREEMENT 

This Agreement shall enter into force on the day of the closing of the Business Combination. This Agreement shall be in full force and effect
for so long as the Indemnitee may have any liability or potential liability by virtue of serving or having served as a member of the Board and / or as an Executive Officer, including, without limitation, the final termination of all pending
Proceedings in respect of which the Indemnitee is entitled to indemnification of Losses or advance of Expenses hereunder and of any Proceeding commenced by the Indemnitee pursuant to Section 6. The Indemnitee’s rights under this Agreement
shall continue after the Indemnitee has ceased to be a member of the Board and / or an Executive Officer. 
  

	9.	 DATA PROTECTION 

The Indemnitee agrees that the Company may forward to its subsidiaries and affiliated entities or any other third party (including, but not
limited to, insurance companies, service providers, courts and public authorities) in Switzerland and / or abroad the Indemnitee’s data for processing purposes. 
  

	10.	 GENERAL PROVISIONS 

 

	10.1	 No Right to Continued Service 

Nothing contained in this Agreement shall be construed as giving the Indemnitee any right to be retained in the employ of the Company or any of
its subsidiaries or affiliated entities. No provision in this Agreement shall confer upon the Indemnitee any right to continue to serve the Company in the capacity in effect at the time this Agreement was executed or shall affect the right of the
Company to terminate the Indemnitee’s contractual relationship with the Company in accordance with such contractual relationship and applicable law. 

  

			
	Indemnification Agreement Oculis Holding AG	  	9/11

	10.2	 Successors and Assignment 

This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective permitted successors and
assigns. 
 None of the Parties shall be entitled to assign all or any part of its rights and obligations under this Agreement without the
prior written consent of the other Party. 
  

	10.3	 Notices 

All notices and other communications made or to be made under this Investment Agreement shall be effective upon receipt and shall be given in
writing by courier, or registered mail to the addressees listed on the first page of this Agreement. 
 Each Party may change or amend the
addresses given in this Agreement or designate additional addresses for the purposes of this Section by giving the other Parties written notice of the new address in the manner set forth in this Section. 

 

	10.4	 Entire Agreement 

This Agreement (including its Appendices) constitutes the entire agreement between the Parties hereto with respect to the subject matter hereof
and supersedes any agreement or understanding that may have been concluded with respect to the subject matter hereof between any of the Parties prior to the date of this Agreement. 

 

	10.5	 Severability 

If at any time any provision of this Agreement or any part thereof is or becomes invalid or unenforceable, then neither the validity nor the
enforceability of the remaining provisions or the remaining part of the provision shall in any way be affected or impaired thereby. The Parties agree to replace the invalid or unenforceable provision or part thereof by a valid or enforceable
provision which shall best reflect the Parties’ original intention and shall to the extent possible achieve the same economic result. 
  

	10.6	 Amendments 

This Agreement (including this Section) may only be modified or amended by a document signed by both Parties. 

 

	10.7	 Waiver of Rights 

No waiver by a Party of a failure of any other Party to perform any provision of this Investment Agreement shall operate or be construed as a
waiver in respect of any other or further failure whether of a similar or different character. 
  

	10.8	 Counterparts 

This Investment Agreement may be executed in as many counterparts as there are Parties to it, each of which shall constitute an original, and
all counterparts shall constitute an original, and all counterparts shall together constitute one and the same instrument. This Agreement and any other document relating to this Agreement, and any amendments hereto or thereto, to the extent signed
and delivered by means of a facsimile machine, electronic signature or e-signature (irrespective of whether the relevant electronic signature or e-signature has been
issued by a provider recognized or accredited under applicable law or not) or other electronic transmission (e.g., email delivery in .pdf format or similar format), shall be treated in all manner and respects as an original contract and shall be
considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. 

  

			
	Indemnification Agreement Oculis Holding AG	  	10/11

	11.	 GOVERNING LAW AND JURISDICTION 

 

	11.1	 Governing Law 

This Agreement and all disputes including those concerning any statute of limitations, set-off claims,
tort claims and interest claims, shall be governed by the substantive laws of Switzerland excluding its conflict of laws rules. 
  

	11.2	 Jurisdiction 

The exclusive place of jurisdiction for any dispute, claim or controversy arising under, out of or in connection with or related to the
Agreement (or subsequent amendments thereof), including, without limitation, disputes, claims or controversies regarding its existence, validity, interpretation, performance, breach or termination, shall be at the domicile of the Company 

[Remainder of this page intentionally left blank] 

  

			
	Indemnification Agreement Oculis Holding AG	  	11/11

 IN WITNESS WHEREOF the Parties have caused this Indemnification Agreement to be duly executed as of the date
first written above. 
  

					
	Signatures	 		 	
			
	Place	 		 	Date
	  
	 		 	  

			
	Oculis Holding AG	 		 	
	Signature	 		 	Signature
	  
	 		 	  

			
	Name	 		 	Name
	Title	 		 	Title
	  
	 		 	
			
	Place	 		 	Date
	  
	 		 	  

			
	[Name]	 		 	
	Signature

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]